Post

New research · Urology
Clinical cancer research : an official journal of the American Association for Cancer Research · 1d
Cohort studyClinical cancer research : an official journal of the American Association for Cancer Research · 2026

A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.

Scott T Tagawa, Charlene Thomas, Abdul Baseet Arham … Joseph Osborne
Read paper
UrologyCohort study

Fractionated 225Ac-J591 dosing showed prostate-specific antigen decline in 60% of patients.

A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.

Scott T Tagawa et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Purpose

To test safety of two regimens at differing levels of radioactivity of PSMA-targeted alpha radionuclide 225Ac-J591.

Methods

With progressive, metastatic androgen pathway modulator resistant prostate cancer were enrolled in two parallel dose-escalation cohorts: (1) fractionated-dose regimen (single cycle of 45 - 65 KBq/kg of 225Ac-J591 on day 1 and day 15; main cohort agnostic to prior receipt of 177Lu-PSMA, additional cohort post 177Lu-PSMA) and (2) multiple cycles of 225Ac-J591 (45 - 65 KBq/kg administered every 6 weeks for up to 4 cycles).

n = 42 patients
Results

patients had a significant drop in their PSA levels, a prostate cancer marker

fractionated cohorts
60%
multiple cycle
28%
More results

All received > 1 prior AR pathway inhibitor, 72% chemotherapy, 18% 177Lu-PSMA.

Seven had DLT in multiple cycle regimen; this regimen is not recommended for further development.

More results

Amongst adverse events of special interest, temporary hematologic toxicity was most common [93% thrombocytopenia (32% grade >3), 65% neutropenia (13% grade >3), 63% anemia (20% grade >3)]; dry mouth occurred in 62% (2% grade 2).

“
Conclusion

Fractionated dosing of 225Ac-J591 appears promising. Further investigation is underway.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Review
41.6%
Share with new overactive bladder (sudden urgency, frequent urination) at 20 years
Animal / Preclinical
55.8%
Multidrug resistance found in more than half of cat urine bacteria, limiting treatment options.
Study
91%
Treatment plans agreed with the reference scan in 30 of 33 patients
Case-control
OR = 4.23
Higher triglycerides linked to higher odds of prostate cancer (odds, not risk)
Randomized Trial
60%
Cumulative mortality was 60% with beta-glucan, reduced from 100% in untreated fish.
Cohort Study
HR 2.59
sudden kidney damage meant over twice the risk of death for CAR-T recipients
Study
30%
About 30% of peptides from multiple myeloma cell lines stimulated CD8+ T-cell responses.